Biography

• Professor Lu Shun currently serves as associate editor for Journal of Thoracic Oncology, Lung Cancer, and editor for The Oncologist. Professor. Lu is the committee member of ASCO (Amercian  Society of Clinical of Clinical Oncology ) Asia Pacific Regional Council. He is also the committee member of the International Lung Cancer Research Association. He is the executive board member of Oncology Society Chinese Medical Association. He is also the executive board member of CSCO (Chinese Society of Clinical of Clinical Oncology) and the past chair of Chinese Lung Cancer Association . Professor Lu’s other appointment include past director of Oncology Society Chinese Medical Association Shanghai Branch. He completed his Fellowship of Clinical Oncology in Tel Viv University, Israel, 1996-1997. Further he received the position of Visiting Professor in the Department of Thoracic/Head and Neck Medical oncology at the University of Texas MD Anderson Cancer in Houston, Texas, USA from 2004-2005.

• Professor Lu served as the leading PI for more than 80 multi-center Phase III oncology clinical trials and participated as the key contributor for more than 70 global and regional clinical trials as well. He has authored more than 200 peer-reviewed articles, many of which has published at Lancet Oncology, JCO, Lancet Respiratory Medicine, Annuals of Oncology, PNAS, Clinical Cancer Research, Chest and JTO etc. (total IF: 889.9)

• Professor Lu presided severl progrsm included：National Program on Key Basic Research Project of China；National new drug innovation major project ; Chinese National Science and Technology Promotion Co-operation project；National Natural Science Foundation of China；863 High-Tech R＆D Program

Awards

• First prize of Science and Technology Award of China anti-cancer Association(2020)

• Second Prize, Science and Technology Award, Chinese Medical Association(2021)

• First prize of Shanghai Medical Science and Technology Award(2021)

• Second Prize of Huaxia Medical Science and Technology Award(2019)

• First Prize of Shanghai Scientific and Technology Progress(2019)

• Second Prize of Shanghai anti-cancer association(2017)

• 2021 Wuxi Apptech-award for the transformation of scientific and technological achievements

Select Publications

1. Shun Lu, Lin Wu, Hong Jian, Ying Chen, Qiming Wang, Jian Fang, Ziping Wang, Yanping Hu, Meili Sun, Liang Han, Liyun Miao, Cuimin Ding, Jiuwei Cui, Baolan Li, Yueyin Pan, Xingya Li, Feng Ye, Anwen Liu, Ke Wang, Shundong Cang, Hui Zhou, Xing Sun, David Ferry, Yong Lin, Shuyan Wang, Wen Zhang, Chengli Zhang.  Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022 Sep;23(9):1167-1179（first and corresponding author）

2. Zhen Zhou, Zhengping Ding, Jie Yuan, Shengping Shen, Hong Jian, Qiang Tan, Yunhai Yang, Zhiwei Chen, Qingquan Luo, Xinghua Cheng, Yongfeng Yu, Xiaomin Niu, Liqiang Qian, Xiaoke Chen, Linping Gu, Ruijun Liu, Shenglin Ma, Jia Huang, Tianxiang Chen, Ziming Li, Wenxiang Ji, Liwei Song, Lan Shen, Long Jiang, Zicheng Yu, Chao Zhang, Zaixian Tai, Changxi Wang, Rongrong Chen, David P Carbone, Xuefeng Xia, Shun Lu. Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno neoadjuvant therapy in NSCLC patients. Journal of Hematology & Oncology. 2022 May 18;15(1):62. （corresponding author）

3. Shun Lu , Xiaorong Dong , Hong Jian , Jianhua Chen , Gongyan Chen , Yuping Sun 5, Yinghua Ji , Ziping Wang , Jianhua Shi , Junguo Lu , Shaoshui Chen , Dongqing Lv , Guojun Zhang, Chunling Liu, Juan Li, Xinmin Yu, Zhong Lin, Zhuang Yu, Zhehai Wang, Jiuwei Cui, Xingxiang Xu, Jian Fang, Jifeng Feng, Zhi Xu, Rui Ma, Jie Hu, Nong Yang, Xiangdong Zhou, Xiaohong Wu, Chengping Hu, Zhihong Zhang, You Lu, Yanping Hu, Liyan Jiang, Qiming Wang, Renhua Guo, Jianying Zhou, Baolan Li, Chunhong Hu, Wancheng Tong, Helong Zhang, Lin Ma, Yuan Chen, Zhijun Jie, Yu Yao, Longzhen Zhang, Weng Jie, Weidong Li, Jianping Xiong , Xianwei Ye, Jianchun Duan, Haihua Yang, Meili Sun, Changan Sun, Hongying Wei, Chuan Li, Siraj M Ali, Vincent A Miller, Qiong Wu. Aeneas: A Randomized Phase 3 Trial of Aumolertinib vs, Gefitinib as First-Line Therapy for Locally Advanced or Metastatic NSCLC With EGFR Exon 19 Deletion or L858R Mutation.J Clin Oncol. 2022 Sep 20;40(27):3162-3171.（first and corresponding author）

4. Shun Lu, Qiming Wang, Guojun Zhang, Xiaorong Dong, Cheng-Ta Yang, Yong Song, Gee-Chen Chang, You Lu, Hongming Pan, Chao-Hua Chiu, Zhehai Wang, Jifeng Feng, Jianying Zhou, Xingxiang Xu, Renhua Guo, Jianhua Chen, Haihua Yang, Yuan Chen, Zhuang Yu, Her-Shyong Shiah, Chin-Chou Wang, Nong Yang, Jian Fang, Ping Wang, Kai Wang, Yanping Hu, Jianxing He, Ziping Wang, Jianhua Shi, Shaoshui Chen, Qiong Wu, Changan Sun, Chuan Li, Hongying Wei, Ying Cheng, Wu-Chou Su, Te-Chun Hsia, Jiuwei Cui, Yuping Sun, Sai-Hong Ignatius Ou, Viola W Zhu, James Chih-Hsin Yang. Efficacy of Aumolertinib (HS-10296) in Patients with Advanced EGFR T790M+NSCLC: Updated Post NMPA-approval Results from the APOLLO Registrational Trial. J Thorac Oncol. 2022 Mar;17(3):411-422. （first and corresponding author）

5. Shun Lu, Jian Fang, Xingya Li, Lejie Cao, Jianying Zhou, Qisen Guo, Zongan Liang, Ying Cheng, Liyan Jiang, Nong Yang, Zhigang Han, Jianhua Shi, Yuan Chen, Hua Xu, Helong Zhang, Gongyan Chen, Rui Ma, Sanyuan Sun, Yun Fan, Jing Li, Xian Luo, Linfang Wang, Yongxin Ren, WeiguoSu. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. Lancet Respir Med. 2021 Oct;9(10):1154-1164. （first and corresponding author）

6. Shun Lu, Jie Wang, Yan Yu, Xinmin Yu, Yanping Hu, Xinghao Ai, Zhiyong Ma, Xingya Li, MD,Wu Zhuang, MD, Yunpeng Liu, Weidong Li, Jiuwei Cui, Dong Wang, Wangjun Liao, Jianying Zhou, Zhehai Wang, Yuping Sun, Xiusong Qiu, Jie Gao, Yuanyuan Bao, Liang Liang, Mengzhao Wang. Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial.J Thorac Oncol..2021,16 (9):1512–1522. （first and corresponding author）

7. Shun Lu, Jianhua Chang, Xiaoqing Liu, Jianhua Shi, You Lu, Wei Li, Jin-Ji Yang, Jianying Zhou, Jie Wang, Tongtong An, Lei Yang, Zhe Liu, Xiangdong Zhou, Mo Chen, Ye Hua, WeiguoSu.Randomized, Double-Blind, Placebo-Controlled,Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non‒Small-Cell Lung Cancer.J Clin Oncol，2018 Apr 20;36(12):1207-1217. （first and corresponding author）

8. Xinghao Ai, Qiming Wang, Ying Cheng, Xiaoqing Liu, Lejie Cao, Jianhua Chen, Xiaorong Dong, Jianying Zhou, Yun Fan, Cheng Huang, Jiuwei Cui, Yan Wang, Gongyan Chen, Cuimin Ding, Beili Gao, Xingya Li, Ziping Wang, Helong Zhang, Lieming Ding , Yang Wang, Xiaobin Yuan, Hongke Cheng, Tao Wang , Shun Lu.Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study. Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study. J Thorac Oncol. 2021 Nov;16(11):1959-1963. （corresponding author）

9. Shun Lu , Zhiwei Chen, Chengping Hu, Jian Zhang, Yuan Chen, Yong Song, Qiong Zhao, Yun Fan, Gang Wu, Zhiyong Ma , Jian Fang, Qitao Yu, Zhe Liu.Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung - A Multicenter, Open-label, Randomized, Phase III Trial，J Thorac Oncol.2018 Nov;13(11):1743-1749. （first and corresponding author）

10. Xinghao Ai, Yueyin Pan, Jianhua Shi, Nong Yang, Chunling Liu, Jianying Zhou, Xiaodong Zhang, Xiaorong Dong, Jianxing He, Xiaoling Li, Gongyan Chen, Xingya Li, Helong Zhang, Wangjun Liao, Yiping Zhang, Zhiyong Ma, Liyan Jiang, Jiuwei Cui, Chunhong Hu, Wei Wang , Cheng Huang , Jun Zhao, Cuimin Ding , Xiaohua Hu, Kai Wang , Beili Gao, Yong Song, Xiaoqing Liu, Jianping Xiong, Anwen Liu, Junling Li, Zhe Liu, Yinyin Li, Mengzhao Wang, Biao Zhang, Dan Zhang, Shun Lu. Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study. J Thorac Oncol. 2021 Aug;16(8):1403-1414. （corresponding author）

11. Yin Tang, Zhuo Wang, Ziming Li, Jungwoo Kim, Yuliang Deng, Yan Li, James R Heath, Wei Wei, Shun Lu, Qihui Shi. High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients.Proc Natl Acad Sci U S A.2017 Mar 7;114(10):2544-2549. （corresponding author）

12. Ziming Li, Zhuo Wang, Yin Tang, Xiang Lu, Jie Chen, Yu Dong, Baojun Wu, Chunying Wang, Liu Yang, Zhili Guo, Min Xue, Shun Lu, Wei Wei, Qihui Shi.Liquid biopsy-based single-cell metabolic phenotyping of lung cancer patients for informative diagnostics. Nat Commun. 2019 Aug 26;10(1):3856. （corresponding author）

13. Liu Yang, Xiaowei Yan, Jie Chen, Qiong Zhan, Yingqi Hua, Shili Xu, Ziming Li, Zhuo Wang , Yu Dong, Dongqing Zuo, Min Xue, Yin Tang, Harvey R Herschman, Shun Lu, Qihui Shi, Wei Wei. Hexokinase 2 discerns a novel circulating tumor cell population associated with poor prognosis in lung cancer patients. Proc Natl Acad Sci U S A. 2021 Mar 16;118(11):e2012228118. （corresponding author）

14. Xiaomin Niu, Hongxuan Li, Zhiwei Chen, Yun Liu, Mengyuan Kan, Daizhan Zhou, Ziming Li, Xiangyun Ye, Shengping Shen, ChangxingLv, Shun Lu. A study of ethnic differences in TGFβ1 gene polymorphisms and effects on the risk of radiation pneumonitis in non-small-cell lung cancer.J Thorac Oncol. 2012 Nov;7(11):1668-75. （corresponding author）

15. Ziming Li, Lan Shen, Ding Ding, Jia Huang, Jie Zhang, Zhiwei Chen, Shun Lu. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer，J Thorac Oncol. 2018 Jul;13(7):987-995. （corresponding author）

16. Xiaomin Niu, Fatao Liu, Yi Zhou, Zhen Zhou, Daizhan Zhou, Ting Wang, Ziming Li, Xiangyun Ye, Yongfeng Yu, Xiaoling Weng, Hong Zhang, Junyi Ye , Meilin Liao, Yun Liu , Zhiwei Chen, Shun Lu.Genome-wide DNA Methylation Analysis Reveals GABBR2 as a Novel Epigenetic Target for EGFR 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment.Clin Cancer Res. 2017 Sep 1;23(17):5003-5014. （corresponding author）

17. Xinghao Ai , Jiuwei Cui, Jiexia Zhang , Rongrong Chen, Wen Lin, Congying Xie, Anwen Liu, Junping Zhang, Weihua Yang, Xiaohua Hu, Xiaohua Hu, Qiong Zhao, Chuangzhou Rao, Yuan-Sheng Zang, Ruiling Ning, Pansong Li, Lianpeng Chang, Xin Yi, Shun Lu.Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641). Clin Cancer Res. 2021 Feb 1;27(3):704-712. （corresponding author）

18. Shun Lu, Yongfeng Yu, Ziming Li, Ruoying Yu, Xue Wu, Hairong Bao, Yan Ding, Yang W Shao, Hong Jian. EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer. J Thorac Oncol. 2019 Apr;14(4):732-736. （first and corresponding author）

19. YuepingJin, Hui Dong, Liliang Xia, Yi Yang, Yongqiang Zhu, Yan Shen, Huajun Zheng , Chengcheng Yao, Ying Wang, Shun Lu.The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti–Programmed Death 1Immunotherapy in Chinese Patients With NSCLC. J Thorac Oncol. 2019 Aug;14(8):1378-1389. （corresponding author）